Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Biopsies from advanced melanoma before and/or after treatment with nivolumab


ABSTRACT: Expression profiling of tumor samples obtained during CA209-038 (ClinicalTrials.gov Identifier: NCT01621490). The purpose of this study is to evaluate pharmacodynamic changes of nivolumab and nivolumab in combination with ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced). Samples are rumor core needle biopsies obtained at trial enrolment (i.e. Screen) and/or at Cycle 1 Day 29 (i.e.Week 4) from Subjects With Advanced Melanoma (Unresectable or Metastatic) treated with nivolumab (BMS-936558,MDX-1106) 3 mg/kg solution intravenously every 2 weeks on Bristol-Myers Squibb clinical trial protocol CA209-038 Part 1 . Cohort 2 patients have progressed on anti-CTLA4 (ipilimumab) monoclonal antibody therapy. Values are from an interim lock of the trial data in July 2014. Best overall response (BOR) was defined using RECIST 1.1 criteria: tumor assessments between date of first dose and the date of first objectively documented progression, or the date of non-missing subsequent anti-cancer therapy (whichever occurs first) were used to derive BOR. MPCT is Maximum reduction in tumor size (index lesions only) up to first progression, and is the value typically shown on a waterfall plot.

INSTRUMENT(S): Gene Titan

ORGANISM(S): Homo sapiens

SUBMITTER: Petra Ross-Macdonald 

PROVIDER: E-MTAB-4030 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2022-01-07 | GSE193157 | GEO
2023-12-31 | GSE243572 | GEO
2015-06-23 | GSE70035 | GEO
2019-11-15 | MODEL1911150001 | BioModels
2014-01-08 | E-GEOD-48905 | biostudies-arrayexpress
2015-06-23 | E-GEOD-70035 | biostudies-arrayexpress
| PRJNA578569 | ENA
2014-11-03 | E-GEOD-56493 | biostudies-arrayexpress
2020-05-19 | GSE150787 | GEO
2021-02-19 | GSE167039 | GEO